- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 136
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 104 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 683
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atopic Dermatitis
- Interventions
- Pimecrolimus
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 2 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 0
- States / cities
- Not listed
- Conditions
- Atopic Dermatitis
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Years to 65 Years
- Enrollment
- 111 participants
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Eczema, Atopic Dermatitis
- Interventions
- Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
- Device
- Lead sponsor
- Frankel, Amylynne, M.D.
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Placebo, Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 941 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 57
- States / cities
- North Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 48 more
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo, Rilzabrutinib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 9
- States / cities
- Northridge, California • Colorado Springs, Colorado • Miami, Florida + 5 more
- Conditions
- Smoking, Acne, Atopic Dermatitis, Aging
- Interventions
- Skin Surface Lipid Collection and Skin Barrier Function
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Asthma, Allergic Rhinitis, Atopic Dermatitis
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 100 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2045
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Psoriasis, Atopic Dermatitis, Acne
- Interventions
- Tailored Patient-Provider Communication, Non-Tailored Patient-Provider Communication
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Atopic Dermatitis
- Interventions
- Barzolvolimab, Matching placebo
- Biological · Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Burbank, California + 28 more
- Conditions
- Atopic Dermatitis
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Atopic Dermatitis
- Interventions
- OpSCF, Placebo
- Biological
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 15 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Bermekimab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more
- Conditions
- Atopic Dermatitis, Secondary Infection
- Interventions
- Retapamulin 1%
- Drug
- Lead sponsor
- Derm Research, PLLC
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Interventions
- Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
- Other · Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Cypress, California • Glendale, California • Denver, Colorado + 4 more
- Conditions
- Dermatitis Atopic
- Interventions
- Blood sample, Cheek swab
- Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 0 Years to 11 Years
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Los Angeles, California + 16 more
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab SAR231893
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema
- Interventions
- Crisaborole 2% Top Oint, Skin Microbiome Swabs
- Drug · Genetic
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Atopic Dermatitis
- Interventions
- Abrocitinib 200 mg, Dupilumab 300 mg
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 727 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more
- Conditions
- Atopic Dermatitis
- Interventions
- Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 33
- States / cities
- Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 27 more
- Conditions
- Atopic Dermatitis
- Interventions
- GBR 830, Placebo
- Biological
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 12
- States / cities
- Rogers, Arkansas • Los Angeles, California • San Diego, California + 9 more
- Conditions
- Atopic Dermatitis
- Interventions
- RVT-501 0.2% ointment, RVT-501 0.5% ointment, Vehicle ointment
- Drug · Other
- Lead sponsor
- Dermavant Sciences GmbH
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 16
- States / cities
- Fremont, California • Los Angeles, California • San Diego, California + 10 more